For Information About Current Clinical Trials
More than 1,200 clinical trials, which have contributed to best practice standards for the care of patients.
A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults Who Have Left Ventricular Systolic Dysfunction Following Myocardial Infarction
Description: NP202 is an experimental drug being developed by Armaron Bio Pty Ltd for potential use as a treatment for people after they have had a heart attack (MI).
Drug: NP202; Other: Placebo
Primary Investigator: Kereiakes
The Carl and Edyth Lindner Research Centerat The Christ Hospital
2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219
Join Us on:
Web Design by TBH Creative